Edwards Lifesciences carries best-in-class margins and a consistent earnings beat pattern, but a forward multiple of 25.6x combined with price momentum below the acceptable threshold, a 74% product concentration in a single franchise, and only about 1% headroom to the near-term price target create a risk/reward profile that does not justify adding to the position at current levels.
Thesis pillars
- Best In Class Margins Quality→Stable
- Single Product Concentration Risk↑Improving
- Rich Valuation Weak Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026
Edwards Lifesciences Corporatio (EW) Stock Analysis
Healthcare · Medical Devices
Wait for pullback to $85.19. Price sits above the model's entry target of $85.19; the risk/reward becomes favorable on a pullback. Key risks: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%).
Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net sales), TMTT (9%), and Surgical (17%) — sold through direct sales forces in approximately 100 countries. The U.S. accounted for 58% of 2025 net sales; no single... Read more
Wait for pullback to $85.19. Price sits above the model's entry target of $85.19; the risk/reward becomes favorable on a pullback. Key risks: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Score 5.5/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
About Edwards Lifesciences Corporatio
About Edwards Lifesciences Corporatio
Edwards Lifesciences generated net sales across three structural heart device platforms in 2025: TAVR — led by the SAPIEN family, which has treated over 1.2 million patients since commercial launch in Europe in 2007 — contributed 74% of net sales; TMTT contributed 9%; and Surgical contributed 17%. The U.S. accounted for 58% of 2025 net sales, with international markets in Europe, Japan, and Rest of World comprising the remaining 42%. Research and development spending represented approximately 18% of 2025 sales.
Edwards Lifesciences earns revenue through direct sales forces in approximately 100 countries and, in some markets, through independent distributors and consignment arrangements. TAVR products including the SAPIEN 3 platform are sold to hospitals and health systems that obtain reimbursement from government programs, private insurance, and managed care. Primary competitors in TAVR and Surgical include Medtronic plc and Abbott Laboratories; in TMTT, Abbott is the primary competitor. Manufacturing is conducted at facilities in the United States, Singapore, Costa Rica, and Ireland. The company purchases certain supplies from single sources due to sole-source availability or regulatory constraints; finding alternative qualified suppliers may require significant effort given FDA validation requirements. R&D programs include ongoing clinical trials for TAVR indication expansion, TMTT (PASCAL, EVOQUE, SAPIEN M3), and Surgical platforms.
Show full overview
Edwards Lifesciences manufactures products at overseas facilities in Singapore, Costa Rica, and Ireland while facing potential tariff exposure from the U.S. Department of Commerce's Section 232 investigation into medical device imports under the Trade Expansion Act of 1962. If tariffs are imposed on components or finished goods from these facilities, manufacturing costs could rise, and sourcing alternatives may be time-consuming given FDA regulatory validation requirements for replacement suppliers. This exposure — concentrated foreign manufacturing combined with single-source supply relationships — exposes the company to cost and supply disruption risk that would be difficult to remediate quickly.
See also: Healthcare · Medical Devices
From Edwards Lifesciences Corporatio's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-29Recent Developments — Edwards Lifesciences Corporatio
Latest news
- NEWS Why Are Traders Reassessing Edwards Lifesciences (NYSE:EW)? - Kalkine Media — Kalkine Media neutral
- NEWS Why Are Traders Reassessing Edwards Lifesciences (NYSE:EW)? - kalkinemedia.com — kalkinemedia.com neutral
- NEWS Is EW Overvalued? DCF Says Worth $53 - GuruFocus — GuruFocus negative
- NEWS Edwards Lifesciences stock heads into the open after a 1.26 percent gain - AD HOC NEWS — AD HOC NEWS neutral
- NEWS Edwards Lifesciences stock heads into the open after a 1.26 percent gain - ad-hoc-news.de — ad-hoc-news.de neutral
Generated 2026-10-29T11:08:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTAVR74%10-K Item 1: 'Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.'
- HIGHGeographicUnited States58%10-K Item 1: 'In 2025, 58% of our net sales were derived from sales to customers in the United States.'
- HIGHSuppliersingle-source supplies10-K Item 1: 'we purchase certain supplies from single sources for reasons of sole source availability or constraints resulting from regulatory requirements'
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMTheodora Mistras appointed Corporate VP and CFO effective May 29, 2026, succeeding Scott B. Ullem. Mistras previously served as CFO of Viatris, Inc. since March 2024. No reason cited for Ullem's departure.SEC filing →
- 2026-05-08Item 5.02LOWStockholders approved Amended and Restated Long-Term Stock Incentive Compensation Program at May 7, 2026 Annual Meeting, increasing available shares by 7,000,000 to a total of 341,500,000. Routine compensatory arrangement; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $85.19. Price sits above the model's entry target of $85.19; the risk/reward becomes favorable on a pullback. Key risks: Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Analyst target $91.25 reached (−0.6%), stop $81.35 (−12.8%), A.R:R -0.1:1. Score 5.5/10, moderate confidence.
Analyst target $91.25 reached (−0.6% from $91.78); no take-profit level is published. Analyst target $91.25 reached (−0.6%), stop $81.35 (−12.8%), A.R:R -0.1:1. Stop-loss: $81.35.
Concentration risk — Product: TAVR (74.0%); Concentration risk — Geographic: United States (58.0%); Analyst target reached - limited upside remaining.
Edwards Lifesciences Corporatio trades at a P/E of 54.6 (forward 27.1). TrendMatrix value score: 3.6/10. Verdict: Buy (Wait for Entry).
38 analysts cover EW with a consensus score of 4.2/5. Average price target: $101.
What does Edwards Lifesciences Corporatio do?Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net...
Edwards Lifesciences designs and manufactures structural heart devices across three lines — TAVR (74% of 2025 net sales), TMTT (9%), and Surgical (17%) — sold through direct sales forces in approximately 100 countries. The U.S. accounted for 58% of 2025 net sales; no single customer exceeded 10%. Primary competitors include Medtronic and Abbott, and R&D spending represented approximately 18% of 2025 sales.